158 related articles for article (PubMed ID: 24999743)
21. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ;
J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer in young women from a low risk population in Nepal.
Thapa B; Singh Y; Sayami P; Shrestha UK; Sapkota R; Sayami G
Asian Pac J Cancer Prev; 2013; 14(9):5095-9. PubMed ID: 24175782
[TBL] [Abstract][Full Text] [Related]
23. Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer.
Ferrari N; Mohammed ZM; Nixon C; Mason SM; Mallon E; McMillan DC; Morris JS; Cameron ER; Edwards J; Blyth K
PLoS One; 2014; 9(6):e100759. PubMed ID: 24967588
[TBL] [Abstract][Full Text] [Related]
24. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
26. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
27. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
[TBL] [Abstract][Full Text] [Related]
28. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
Crozier JA; Pezzi TA; Hodge C; Janeva S; Lesnikoski BA; Samiian L; Devereaux A; Hammond W; Audisio RA; Pezzi CM
Lancet Oncol; 2020 Dec; 21(12):1611-1619. PubMed ID: 33271091
[TBL] [Abstract][Full Text] [Related]
29. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
[TBL] [Abstract][Full Text] [Related]
30. A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts.
Mathew J; Lee S; Syed BM; Morgan DA; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2014 Oct; 147(3):671-4. PubMed ID: 25148877
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women.
Honma N; Ogata H; Yamada A; Matsuda Y; Kontani K; Miyashita M; Arai T; Sasaki E; Shibuya K; Mikami T; Sawaki M
Hum Pathol; 2021 May; 111():10-20. PubMed ID: 33548251
[TBL] [Abstract][Full Text] [Related]
32. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Loi S; Michiels S; Salgado R; Sirtaine N; Jose V; Fumagalli D; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Desmedt C; Piccart MJ; Loibl S; Denkert C; Smyth MJ; Joensuu H; Sotiriou C
Ann Oncol; 2014 Aug; 25(8):1544-50. PubMed ID: 24608200
[TBL] [Abstract][Full Text] [Related]
33. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
34. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
35. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
36. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
[TBL] [Abstract][Full Text] [Related]
37. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
38. Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers.
Davion SM; Siziopikou KP; Sullivan ME
Histopathology; 2012 Oct; 61(4):660-6. PubMed ID: 22748158
[TBL] [Abstract][Full Text] [Related]
39. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
40. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.
Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB
Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
